Solid Biosciences Reports Positive Initial Clinical Data from Next ...
Feb 18, 2025 · INSPIRE DUCHENNE is a first-in-human, open-label, single-dose, multicenter Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric …
Investor Relations • Solid Biosciences Inc.
Jan 15, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, …
Solid Biosciences Receives FDA Fast Track Designation for SGT …
Jan 21, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, …
© 2020 Solid Biosciences 15. SGT-001 Clinical Biomarker Results Support Continued Development • Interim results following SGT- 001 administration show dose - dependent, …
Solid Biosciences Reports Inducement Grants Under Nasdaq …
Feb 4, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, …
Solid Biosciences Added to the Nasdaq Biotechnology Index
Dec 23, 2024 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne …
Solid Biosciences Announces Pricing of Underwritten Offering
Feb 18, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, …
Solid Biosciences Reports Inducement Grants Under Nasdaq …
Jan 6, 2025 · Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular …
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by the absence of dystrophin, a membrane-stabilizing protein encoded by the DMD gene. Although …
Solid Biosciences: Pioneering the Next Generation of Precision Genetic Medicines with Multiple Clinical Stage Assets in 2025. Neuromuscular. Cardiac. Delivery. Next-generation …
- Some results have been removed